

Table 1. Number of reports and reporting odds ratios of agranulocytosis associated with antibiotics.

Group	Antibiotics	Total (n)	Case (n)	Non-case (n)	ROR	95%CI
Anti-MRSA agents	Arbekacin	435	3	432	0.74	0.15-2.19
	Linezolid	74	0	74	NA	0.00-5.48
	Teicoplanin	1356	25	1331	2.05	1.31-3.07
	Vancomycin	2428	72	2356	3.54	2.73-4.54
Anti-fungal agents	Amphotericin B	1055	0	1055	NA	0.00-0.37
	Fluconazole	2960	22	2938	0.80	0.49-1.22
	Flucytosine	22	0	22	NA	0.00-19.6
	Fos-fluconazole	2002	24	1978	1.31	0.83-1.97
	Itraconazole	1646	4	1642	0.26	0.07-0.66
	Ketoconazole	125	0	125	NA	0.00-3.21
	Micafungin	2482	3	2479	0.13	0.03-2.40
	Miconazole	351	0	351	NA	0.00-1.13
	Voriconazole	378	0	378	NA	0.00-1.04
Aminoglycoside	Amikacin	1037	27	1010	2.94	1.91-4.34
	Dibekacin	9	0	9	NA	0.00-54.3
	Gentamicin	467	4	463	0.92	0.25-2.40
	Kanamycin	113	6	107	6.05	2.16-13.7
	Streptomycin	183	0	183	NA	0.00-2.18
Quinolone	Ciprofloxacin	2005	36	1969	2.01	1.40-2.82
	Gatifloxacin	673	0	673	NA	0.00-0.58
	Levofloxacin	4267	15	4252	0.36	0.20-0.61
	Norfloxacin	111	0	111	NA	0.00-3.62
	Pazufloxacin	1072	3	1069	0.30	0.06-1.34
	Tosufloxacin	448	1	447	0.24	0.01-0.92
Macrolide	Azithromycin	1508	5	1503	0.35	0.11-0.83
	Clarithromycin	3921	17	3904	0.45	0.26-0.73
	Erythromycin	651	1	650	0.16	0.004-0.92
Carbapenem	Imipenem/cilastatin	2734	65	2669	2.78	2.11-3.60
	Doripenem	18	0	18	NA	0.00-24.41
	Biapenem	535	4	531	0.81	0.22-2.08
	Meropenem	3651	33	3618	0.98	0.67-1.39
Tetracycline	Doxycycline	23	0	23	NA	0.00-18.67
	Minocycline	1908	25	1883	1.44	0.92-2.15
Anti-viral agents	Aciclovir	2012	8	2004	0.42	0.18-0.84
	Valaciclovir	1927	1	1926	0.05	0.00-10.30

Table 1. Number of reports and reporting odds ratios of agranulocytosis associated with antibiotics (continued).

Penicillin	Amoxicillin	805	1	804	0.13	0.003-0.74
	Amoxicillin/clavulanate	59	0	59	NA	0.00-6.92
	Ampicillin	341	0	341	NA	0.00-1.16
	Ampicillin/sulbactam	1365	32	1333	2.65	1.79-3.80
	Benzylpenicillin	18	0	18	NA	0.00-24.43
	Faropenem	187	1	186	0.58	0.01-3.26
	Piperacillin	1670	14	1656	0.90	0.50-1.53
	Piperacillin/tazobactam	535	6	529	1.22	0.44-2.68
Cephalosporin	Cefaclor	439	3	436	0.74	0.15-2.17
	Cefazolin	1446	14	1432	1.05	0.57-1.78
	Cefcapene	2191	4	2187	0.19	0.05-0.49
	Cefditoren	541	2	539	0.40	0.01-1.44
	Cefepime	1572	9	1563	0.61	0.28-1.17
	Cefmetazole	561	22	539	4.48	2.77-6.92
	Cefoperazone/sulbactam	1565	12	1553	0.82	0.43-1.45
	Cefotaxime	259	3	256	1.26	0.26-3.73
	Cefotiam	1884	18	1866	1.03	0.61-1.65
	Cefozopran	1351	33	1318	2.77	1.88-3.95
	Ceftazidime	1408	5	1403	0.38	0.12-0.89
	Cefteram	156	2	154	1.39	0.17-5.13
	Ceftriaxone	1415	12	1403	0.91	0.47-1.61
	Cephalexin	67	0	67	NA	0.00-6.07
	Flomoxef	959	11	948	1.25	0.62-2.26
Lincomycin	Clindamycin	1612	24	1588	1.64	1.04-2.47
Other	Trimethoprim/sulfamethoxazole	5730	47	5683	0.88	0.64-1.18

NA; not available. MRSA: methicillin-resistant *Staphylococcus aureus*. ROR: reporting odds ratio. 95%CI: 95% confidence interval.

Table 2. Time-to-onset analysis of antibiotics using Weibull distributions.

Antibiotics	Case (n)	Median (Day) (25-75%)	Scale parameter: α		Scale parameter: β		Pattern
			α	95%CI	β	95%CI	
Amikacin	25	2 (1-3)	6.76	3.87-11.44	0.80	0.59-1.04	Random failure
Ampicillin/sulbactam	16	20 (14-29)	23.37	18.7-28.8	2.57	1.66-3.70	Wear out failure
Cefmetazole	22	6 (4-8)	6.59	6.62-7.68	2.95	2.09-3.90	Wear out failure
Cefozopran	25	10 (8-17)	12.55	9.32-12.65	1.49	1.03-2.06	Wear out failure
Clindamycin	22	16 (10-23)	18.32	15.6-21.3	2.98	2.06-4.12	Wear out failure
Ciprofloxacin	35	4 (1-8.5)	7.32	4.73-11.10	0.85	0.64-1.07	Random failure
Imipenem/cilastatin	56	12 (9-23)	16.56	14.16-19.27	1.81	1.43-2.24	Wear out failure
Kanamycin	6	3 (2-4)	3.36	2.47-4.48	3.46	1.61-6.35	Wear out failure
Teicoplanin	21	18 (6-20)	16.49	12.76-19.53	2.74	1.82-3.95	Wear out failure
Vancomycin	64	13 (9-20)	17.42	15.40-19.63	2.17	1.78-2.59	Wear out failure

$0 < \beta < 1$, early failure; $\beta = 1$, random failure; $\beta > 1$, wear out failure.

95%CI: 95% confidence interval.